🇺🇸 FDA
Pipeline program

Brigatinib

AP26113-11-101

Phase 2 small_molecule completed

Quick answer

Brigatinib for Lymphoma, Large-Cell, Anaplastic is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Lymphoma, Large-Cell, Anaplastic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials